Should I buy Tandem Diabetes Care (TNDM) stock or is it too late?
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
Firm-by-firm track record on Tandem Diabetes Care
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Piper Sandler | 30 % | +31.5 % | 10 | $33 +98% |
| Canaccord Genuity | 50 % | +5.0 % | 6 | $35 +110% |
| Barclays | 50 % | -3.5 % | 8 | $18 +8% |
| Citigroup | 38 % | -11.6 % | 8 | $20 +20% |
| Wells Fargo | 25 % | -36.4 % | 8 | $27 +62% |
| Deutsche Bank | 0 % | -45.3 % | 5 | $16 -7% |
| Stifel | 0 % | -45.4 % | 7 | $22 +32% |
| Raymond James | 50 % | -14.3 % | 12 | — |
✅ Reasons to believe
- Median price target $25, i.e. +50% from the current price ($17).
- The most reliable firm on TNDM, UBS (100% hit rate, 3 scored calls), targets $22 (call made on February 20, 2026, maturing on February 20, 2027) (+32%) in its most recent call.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 11 ratings, 6 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on TNDM
Median target $25 (+50%) · 11 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Tandem Diabetes Care now?
We won't decide for you. The facts: 45% of analysts rate it a buy, median target $25 (+50%), and UBS (most reliable on TNDM, 100%) targets $22. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Tandem Diabetes Care?
Not according to analysts: the median target ($25) is still +50% above the current price ($17) (most reliable on TNDM: UBS, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Tandem Diabetes Care still worth investing in?
It depends on the gap between the price ($17) and its estimated value: analysts target $25 on median (+50%), with 45% buys (most reliable on TNDM: UBS, 100%). Cross-check with their real reliability on TNDM and the cautions above. Information, not advice.
What's the main risk in buying TNDM?
The consensus is not unanimous: of 11 ratings, 6 are neutral.
→ Go deeper: the full Tandem Diabetes Care profile (consensus, analyst reliability, price target, performance).